HRP20241435T1 - Nova upotreba agonista angiotenzinskog ii receptora tipa 2 - Google Patents

Nova upotreba agonista angiotenzinskog ii receptora tipa 2 Download PDF

Info

Publication number
HRP20241435T1
HRP20241435T1 HRP20241435TT HRP20241435T HRP20241435T1 HR P20241435 T1 HRP20241435 T1 HR P20241435T1 HR P20241435T T HRP20241435T T HR P20241435TT HR P20241435 T HRP20241435 T HR P20241435T HR P20241435 T1 HRP20241435 T1 HR P20241435T1
Authority
HR
Croatia
Prior art keywords
use according
respiratory
compound
virus
pharmaceutically acceptable
Prior art date
Application number
HRP20241435TT
Other languages
English (en)
Croatian (hr)
Inventor
Carl-Johan Dalsgaard
Johan Raud
Rohit Batta
Original Assignee
Vicore Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004209.9A external-priority patent/GB202004209D0/en
Priority claimed from GBGB2009574.1A external-priority patent/GB202009574D0/en
Priority claimed from US17/113,616 external-priority patent/US20210176086A1/en
Application filed by Vicore Pharma Ab filed Critical Vicore Pharma Ab
Publication of HRP20241435T1 publication Critical patent/HRP20241435T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20241435TT 2020-03-23 2021-03-22 Nova upotreba agonista angiotenzinskog ii receptora tipa 2 HRP20241435T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2004209.9A GB202004209D0 (en) 2020-03-23 2020-03-23 New use
GBGB2009574.1A GB202009574D0 (en) 2020-06-23 2020-06-23 New use
US17/113,616 US20210176086A1 (en) 2019-12-09 2020-12-07 Notification control device, notification control system, and notification control method
PCT/GB2021/050699 WO2021191592A1 (en) 2020-03-23 2021-03-22 New use of angiotensin ii type 2 receptor agonist
EP21715306.3A EP4125881B1 (en) 2020-03-23 2021-03-22 New use of angiotensin ii type 2 receptor agonist

Publications (1)

Publication Number Publication Date
HRP20241435T1 true HRP20241435T1 (hr) 2024-12-20

Family

ID=77747178

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20241435TT HRP20241435T1 (hr) 2020-03-23 2021-03-22 Nova upotreba agonista angiotenzinskog ii receptora tipa 2

Country Status (12)

Country Link
US (2) US11123329B1 (cg-RX-API-DMAC7.html)
EP (1) EP4125881B1 (cg-RX-API-DMAC7.html)
JP (1) JP7671305B2 (cg-RX-API-DMAC7.html)
CN (1) CN115605201A (cg-RX-API-DMAC7.html)
CA (1) CA3176108A1 (cg-RX-API-DMAC7.html)
ES (1) ES2992423T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241435T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068662T2 (cg-RX-API-DMAC7.html)
PL (1) PL4125881T3 (cg-RX-API-DMAC7.html)
RS (1) RS66072B1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400427T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021191592A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
US20220233480A1 (en) * 2020-03-23 2022-07-28 Vicore Pharma Ab Use of angiotensin ii type 2 receptor agonist
JP7798791B2 (ja) * 2020-04-22 2026-01-14 エアウェイ・セラピューティクス・インコーポレイテッド ウイルス感染症の治療のための肺サーファクタントタンパク質dの使用
CN117209555B (zh) * 2021-09-30 2024-12-03 中国科学院上海药物研究所 一类氰基化合物、其制备方法及用途
CN115583984A (zh) * 2022-01-11 2023-01-10 嘉兴安谛康生物科技有限公司 氮杂螺类化合物及其制备方法、药物组合物和用途
CN114948950A (zh) * 2022-01-19 2022-08-30 广州谷森制药有限公司 一种药物组合物及其抗病毒用途
TW202432112A (zh) * 2023-01-16 2024-08-16 大陸商海南先聲藥業有限公司 抗病毒藥物組合物及其製備方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
EP1723962A1 (en) 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
HK1244232A1 (zh) 2015-03-02 2018-08-03 维科尔药物公司 用於治疗肺纤维化的血管紧张素ii受体激动剂
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition

Also Published As

Publication number Publication date
HUE068662T2 (hu) 2025-01-28
JP7671305B2 (ja) 2025-05-01
CN115605201A (zh) 2023-01-13
WO2021191592A1 (en) 2021-09-30
ES2992423T3 (es) 2024-12-12
PL4125881T3 (pl) 2024-12-02
SMT202400427T1 (it) 2024-11-15
US11123329B1 (en) 2021-09-21
EP4125881B1 (en) 2024-07-24
CA3176108A1 (en) 2021-09-30
RS66072B1 (sr) 2024-11-29
EP4125881A1 (en) 2023-02-08
US20210386712A1 (en) 2021-12-16
JP2023520323A (ja) 2023-05-17
EP4125881C0 (en) 2024-07-24
US20210290596A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
JP2023520323A5 (cg-RX-API-DMAC7.html)
AU631711B2 (en) An aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
HRP20191257T1 (hr) Farmaceutske formulacije koje sadrže 4-{(1r)-2-[(6-{2-[(2,6-diklorbenzil)oksi]etoksi}heksil)amino]-1-hidroksietil}-2-(hidroksimetil)fenol
EP4232073B1 (en) New dosage regimen for inhaled vasoactive intestinal polypeptide
RU2007119721A (ru) Частицы для лечения легочной инфекции
JP2025508656A5 (cg-RX-API-DMAC7.html)
EP2488205A1 (en) Recombinant human cc10 protein for treatment of influenza
CN111265500A (zh) 一种防治covid-19的药物组合物及其制备方法
CN112386595A (zh) 一种治疗呼吸系统病毒性感染的药物组合物
EP2285393B1 (en) Compositions for the treatment of disorders of the upper respiratory tract and influenza syndromes
JP2022546424A5 (cg-RX-API-DMAC7.html)
CN105853999A (zh) 干扰素λ的雾化吸入剂
JP2002348240A (ja) 医薬組成物
WO2016036273A1 (ru) Лекарственное средство для профилактики и лечения заболеваний дыхательных путей
US11724077B2 (en) Therapeutic swabs for treating upper respiratory infections
KR880003973A (ko) 약리적 활성 화합물 및 용도
JPH09227373A (ja) 抗インフルエンザウイルス剤
Johnston Cromolyns: treatment for the common cold?
Haff et al. The nasal decongestant action of aspirin in influenza infected ferrets
Benke et al. Development of NSAID-containing dry powder inhalation formulation co-spray-dried with sodium stearate
EP2133089A1 (en) Compositions for the treatment of disorders of the upper respiratory tract and influenza syndromes
TR202100552A2 (tr) Covid-19 ve di̇ğer vi̇ral akci̇ğer hastaliklarinin semptomlarinda ti̇treşi̇mli̇ elek teknoloji̇si̇ nebuli̇zatör i̇le anti̇koagülanlarin i̇nhale kullanilmasi
WO2024019519A1 (ko) iCP-NI를 포함하는 싸이토카인 폭풍 또는 염증성 질환의 치료 또는 예방용 약학적 조성물
AU605580B2 (en) Aerosolization of protein therapeutic agent
WO2000035472A3 (en) Cytokine combination therapy